Julie Laurin

Corporate Officer/Principal at Alethia Biotherapeutics, Inc.

Health Technology

Consumer Services

Consumer Non-Durables

Profile

Julie Laurin is a professional who currently works as the Director of Preclinical Drug Development at Alethia Biotherapeutics, Inc. She previously worked as the Director of Preclinical & Clinical Research at BELLUS Health, Inc. and as the Vice President of Business Development at DAVIDsTEA, Inc. from 2019 to 2020.
Dr. Laurin holds a doctorate degree from the University of Montréal.

Julie Laurin active positions

Companies	Position	Start
Alethia Biotherapeutics, Inc. Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada.	Corporate Officer/Principal	-

All active positions of Julie Laurin

Former positions of Julie Laurin

Companies	Position	End
DAVIDSTEA INC.	Corporate Officer/Principal	01/05/2020
BELLUS HEALTH	Corporate Officer/Principal	-

See the detail of Julie Laurin's experience

Training of Julie Laurin

University of Montréal

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Julie Laurin's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
DAVIDSTEA INC.	Consumer Non-Durables

Private companies	2
BELLUS Health, Inc. BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.	Health Technology
Alethia Biotherapeutics, Inc. Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada.	Health Technology